Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024

Core Points - Vericel Corporation, a leader in advanced therapies for sports medicine and severe burn care, will report its second-quarter 2024 financial results on August 1, 2024 [2] - The management will host a conference call and webcast at 8:30 a.m. (ET) to discuss financial results and business highlights [2] Company Overview - Vericel is a leading provider of advanced therapies, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [5] - The company markets three products in the United States: - MACI® for repairing full-thickness cartilage defects of the knee [5] - Epicel® as a permanent skin replacement for deep dermal or full-thickness burns [5] - NexoBrid®, licensed for North American rights, indicated for the removal of eschar in burn patients [5]